Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs
The last 50years of hepatitis B research has resulted in the development of effective screening assays for surveillance, vaccines for prevention and antiviral drugs that significantly improve patient clinical outcomes. Not surprisingly then, the global epidemiology of hepatitis B virus (HBV) is set...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Locarnini, Stephen [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2015transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
11 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Identification of the antigenic region of - Abdelbaky, Hanan H. ELSEVIER, 2018, official journal of the European Association for the Study of the Liver, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:62 ; year:2015 ; number:1 ; pages:76-86 ; extent:11 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.jhep.2015.01.018 |
|---|
| Katalog-ID: |
ELV012879878 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV012879878 | ||
| 003 | DE-627 | ||
| 005 | 20230625111223.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180602s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jhep.2015.01.018 |2 doi | |
| 028 | 5 | 2 | |a GBVA2015006000007.pica |
| 035 | |a (DE-627)ELV012879878 | ||
| 035 | |a (ELSEVIER)S0168-8278(15)00049-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.44 |2 bkl | ||
| 100 | 1 | |a Locarnini, Stephen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs |
| 264 | 1 | |c 2015transfer abstract | |
| 300 | |a 11 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a The last 50years of hepatitis B research has resulted in the development of effective screening assays for surveillance, vaccines for prevention and antiviral drugs that significantly improve patient clinical outcomes. Not surprisingly then, the global epidemiology of hepatitis B virus (HBV) is set to change dramatically over the next decade. For example, the success and the high coverage of universal HBV vaccination and the ageing cohorts of patients with chronic hepatitis B (CHB) will result in reductions of incidence and prevalence of chronic hepatitis, cirrhosis and probably hepatocellular carcinoma. This will be further accelerated by the impressive progress in the treatment outcomes for patients with CHB. In spite of this success, challenges remain, such as planning for the impact of migration from countries with high prevalence rates to those countries with low rates of HBV infection. The recent establishment of the World Health Organisation Global Hepatitis Program with the provision of a framework for global action has become the cornerstone for all countries to now frame their own particular national responses to control hepatitis B. An effective policy framework can prevent new infections, ensure people can access clinical care, and in doing so reduce the burden of infection at an individual, country and regional level. These developments present a real opportunity to reduce the significant, social and economic burden of global hepatitis B, ultimately the critical next steps to render the world hepatitis B free. | ||
| 520 | |a The last 50years of hepatitis B research has resulted in the development of effective screening assays for surveillance, vaccines for prevention and antiviral drugs that significantly improve patient clinical outcomes. Not surprisingly then, the global epidemiology of hepatitis B virus (HBV) is set to change dramatically over the next decade. For example, the success and the high coverage of universal HBV vaccination and the ageing cohorts of patients with chronic hepatitis B (CHB) will result in reductions of incidence and prevalence of chronic hepatitis, cirrhosis and probably hepatocellular carcinoma. This will be further accelerated by the impressive progress in the treatment outcomes for patients with CHB. In spite of this success, challenges remain, such as planning for the impact of migration from countries with high prevalence rates to those countries with low rates of HBV infection. The recent establishment of the World Health Organisation Global Hepatitis Program with the provision of a framework for global action has become the cornerstone for all countries to now frame their own particular national responses to control hepatitis B. An effective policy framework can prevent new infections, ensure people can access clinical care, and in doing so reduce the burden of infection at an individual, country and regional level. These developments present a real opportunity to reduce the significant, social and economic burden of global hepatitis B, ultimately the critical next steps to render the world hepatitis B free. | ||
| 650 | 7 | |a Prevention |2 Elsevier | |
| 650 | 7 | |a Treatment |2 Elsevier | |
| 650 | 7 | |a Chronic hepatitis B |2 Elsevier | |
| 650 | 7 | |a Hepatitis B vaccine |2 Elsevier | |
| 650 | 7 | |a Hepatocellular carcinoma |2 Elsevier | |
| 650 | 7 | |a Chronic liver disease |2 Elsevier | |
| 650 | 7 | |a Public policy |2 Elsevier | |
| 650 | 7 | |a Epidemiology |2 Elsevier | |
| 650 | 7 | |a Acute hepatitis B |2 Elsevier | |
| 650 | 7 | |a WHO |2 Elsevier | |
| 700 | 1 | |a Hatzakis, Angelos |4 oth | |
| 700 | 1 | |a Chen, Ding-Shinn |4 oth | |
| 700 | 1 | |a Lok, Anna |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Abdelbaky, Hanan H. ELSEVIER |t Identification of the antigenic region of |d 2018 |d official journal of the European Association for the Study of the Liver |g Amsterdam [u.a.] |w (DE-627)ELV000433829 |
| 773 | 1 | 8 | |g volume:62 |g year:2015 |g number:1 |g pages:76-86 |g extent:11 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.jhep.2015.01.018 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.44 |j Parasitologie |x Medizin |q VZ |
| 951 | |a AR | ||
| 952 | |d 62 |j 2015 |e 1 |h 76-86 |g 11 |y 62.2015, 1, S76-, (11 S.) | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
s l sl |
|---|---|
| matchkey_str |
locarninistephenhatzakisangeloschendings:2015----:taeisootohpttspbiplceieil |
| hierarchy_sort_str |
2015transfer abstract |
| bklnumber |
44.44 |
| publishDate |
2015 |
| allfields |
10.1016/j.jhep.2015.01.018 doi GBVA2015006000007.pica (DE-627)ELV012879878 (ELSEVIER)S0168-8278(15)00049-5 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.44 bkl Locarnini, Stephen verfasserin aut Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs 2015transfer abstract 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The last 50years of hepatitis B research has resulted in the development of effective screening assays for surveillance, vaccines for prevention and antiviral drugs that significantly improve patient clinical outcomes. Not surprisingly then, the global epidemiology of hepatitis B virus (HBV) is set to change dramatically over the next decade. For example, the success and the high coverage of universal HBV vaccination and the ageing cohorts of patients with chronic hepatitis B (CHB) will result in reductions of incidence and prevalence of chronic hepatitis, cirrhosis and probably hepatocellular carcinoma. This will be further accelerated by the impressive progress in the treatment outcomes for patients with CHB. In spite of this success, challenges remain, such as planning for the impact of migration from countries with high prevalence rates to those countries with low rates of HBV infection. The recent establishment of the World Health Organisation Global Hepatitis Program with the provision of a framework for global action has become the cornerstone for all countries to now frame their own particular national responses to control hepatitis B. An effective policy framework can prevent new infections, ensure people can access clinical care, and in doing so reduce the burden of infection at an individual, country and regional level. These developments present a real opportunity to reduce the significant, social and economic burden of global hepatitis B, ultimately the critical next steps to render the world hepatitis B free. The last 50years of hepatitis B research has resulted in the development of effective screening assays for surveillance, vaccines for prevention and antiviral drugs that significantly improve patient clinical outcomes. Not surprisingly then, the global epidemiology of hepatitis B virus (HBV) is set to change dramatically over the next decade. For example, the success and the high coverage of universal HBV vaccination and the ageing cohorts of patients with chronic hepatitis B (CHB) will result in reductions of incidence and prevalence of chronic hepatitis, cirrhosis and probably hepatocellular carcinoma. This will be further accelerated by the impressive progress in the treatment outcomes for patients with CHB. In spite of this success, challenges remain, such as planning for the impact of migration from countries with high prevalence rates to those countries with low rates of HBV infection. The recent establishment of the World Health Organisation Global Hepatitis Program with the provision of a framework for global action has become the cornerstone for all countries to now frame their own particular national responses to control hepatitis B. An effective policy framework can prevent new infections, ensure people can access clinical care, and in doing so reduce the burden of infection at an individual, country and regional level. These developments present a real opportunity to reduce the significant, social and economic burden of global hepatitis B, ultimately the critical next steps to render the world hepatitis B free. Prevention Elsevier Treatment Elsevier Chronic hepatitis B Elsevier Hepatitis B vaccine Elsevier Hepatocellular carcinoma Elsevier Chronic liver disease Elsevier Public policy Elsevier Epidemiology Elsevier Acute hepatitis B Elsevier WHO Elsevier Hatzakis, Angelos oth Chen, Ding-Shinn oth Lok, Anna oth Enthalten in Elsevier Science Abdelbaky, Hanan H. ELSEVIER Identification of the antigenic region of 2018 official journal of the European Association for the Study of the Liver Amsterdam [u.a.] (DE-627)ELV000433829 volume:62 year:2015 number:1 pages:76-86 extent:11 https://doi.org/10.1016/j.jhep.2015.01.018 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.44 Parasitologie Medizin VZ AR 62 2015 1 76-86 11 62.2015, 1, S76-, (11 S.) 045F 610 |
| spelling |
10.1016/j.jhep.2015.01.018 doi GBVA2015006000007.pica (DE-627)ELV012879878 (ELSEVIER)S0168-8278(15)00049-5 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.44 bkl Locarnini, Stephen verfasserin aut Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs 2015transfer abstract 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The last 50years of hepatitis B research has resulted in the development of effective screening assays for surveillance, vaccines for prevention and antiviral drugs that significantly improve patient clinical outcomes. Not surprisingly then, the global epidemiology of hepatitis B virus (HBV) is set to change dramatically over the next decade. For example, the success and the high coverage of universal HBV vaccination and the ageing cohorts of patients with chronic hepatitis B (CHB) will result in reductions of incidence and prevalence of chronic hepatitis, cirrhosis and probably hepatocellular carcinoma. This will be further accelerated by the impressive progress in the treatment outcomes for patients with CHB. In spite of this success, challenges remain, such as planning for the impact of migration from countries with high prevalence rates to those countries with low rates of HBV infection. The recent establishment of the World Health Organisation Global Hepatitis Program with the provision of a framework for global action has become the cornerstone for all countries to now frame their own particular national responses to control hepatitis B. An effective policy framework can prevent new infections, ensure people can access clinical care, and in doing so reduce the burden of infection at an individual, country and regional level. These developments present a real opportunity to reduce the significant, social and economic burden of global hepatitis B, ultimately the critical next steps to render the world hepatitis B free. The last 50years of hepatitis B research has resulted in the development of effective screening assays for surveillance, vaccines for prevention and antiviral drugs that significantly improve patient clinical outcomes. Not surprisingly then, the global epidemiology of hepatitis B virus (HBV) is set to change dramatically over the next decade. For example, the success and the high coverage of universal HBV vaccination and the ageing cohorts of patients with chronic hepatitis B (CHB) will result in reductions of incidence and prevalence of chronic hepatitis, cirrhosis and probably hepatocellular carcinoma. This will be further accelerated by the impressive progress in the treatment outcomes for patients with CHB. In spite of this success, challenges remain, such as planning for the impact of migration from countries with high prevalence rates to those countries with low rates of HBV infection. The recent establishment of the World Health Organisation Global Hepatitis Program with the provision of a framework for global action has become the cornerstone for all countries to now frame their own particular national responses to control hepatitis B. An effective policy framework can prevent new infections, ensure people can access clinical care, and in doing so reduce the burden of infection at an individual, country and regional level. These developments present a real opportunity to reduce the significant, social and economic burden of global hepatitis B, ultimately the critical next steps to render the world hepatitis B free. Prevention Elsevier Treatment Elsevier Chronic hepatitis B Elsevier Hepatitis B vaccine Elsevier Hepatocellular carcinoma Elsevier Chronic liver disease Elsevier Public policy Elsevier Epidemiology Elsevier Acute hepatitis B Elsevier WHO Elsevier Hatzakis, Angelos oth Chen, Ding-Shinn oth Lok, Anna oth Enthalten in Elsevier Science Abdelbaky, Hanan H. ELSEVIER Identification of the antigenic region of 2018 official journal of the European Association for the Study of the Liver Amsterdam [u.a.] (DE-627)ELV000433829 volume:62 year:2015 number:1 pages:76-86 extent:11 https://doi.org/10.1016/j.jhep.2015.01.018 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.44 Parasitologie Medizin VZ AR 62 2015 1 76-86 11 62.2015, 1, S76-, (11 S.) 045F 610 |
| allfields_unstemmed |
10.1016/j.jhep.2015.01.018 doi GBVA2015006000007.pica (DE-627)ELV012879878 (ELSEVIER)S0168-8278(15)00049-5 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.44 bkl Locarnini, Stephen verfasserin aut Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs 2015transfer abstract 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The last 50years of hepatitis B research has resulted in the development of effective screening assays for surveillance, vaccines for prevention and antiviral drugs that significantly improve patient clinical outcomes. Not surprisingly then, the global epidemiology of hepatitis B virus (HBV) is set to change dramatically over the next decade. For example, the success and the high coverage of universal HBV vaccination and the ageing cohorts of patients with chronic hepatitis B (CHB) will result in reductions of incidence and prevalence of chronic hepatitis, cirrhosis and probably hepatocellular carcinoma. This will be further accelerated by the impressive progress in the treatment outcomes for patients with CHB. In spite of this success, challenges remain, such as planning for the impact of migration from countries with high prevalence rates to those countries with low rates of HBV infection. The recent establishment of the World Health Organisation Global Hepatitis Program with the provision of a framework for global action has become the cornerstone for all countries to now frame their own particular national responses to control hepatitis B. An effective policy framework can prevent new infections, ensure people can access clinical care, and in doing so reduce the burden of infection at an individual, country and regional level. These developments present a real opportunity to reduce the significant, social and economic burden of global hepatitis B, ultimately the critical next steps to render the world hepatitis B free. The last 50years of hepatitis B research has resulted in the development of effective screening assays for surveillance, vaccines for prevention and antiviral drugs that significantly improve patient clinical outcomes. Not surprisingly then, the global epidemiology of hepatitis B virus (HBV) is set to change dramatically over the next decade. For example, the success and the high coverage of universal HBV vaccination and the ageing cohorts of patients with chronic hepatitis B (CHB) will result in reductions of incidence and prevalence of chronic hepatitis, cirrhosis and probably hepatocellular carcinoma. This will be further accelerated by the impressive progress in the treatment outcomes for patients with CHB. In spite of this success, challenges remain, such as planning for the impact of migration from countries with high prevalence rates to those countries with low rates of HBV infection. The recent establishment of the World Health Organisation Global Hepatitis Program with the provision of a framework for global action has become the cornerstone for all countries to now frame their own particular national responses to control hepatitis B. An effective policy framework can prevent new infections, ensure people can access clinical care, and in doing so reduce the burden of infection at an individual, country and regional level. These developments present a real opportunity to reduce the significant, social and economic burden of global hepatitis B, ultimately the critical next steps to render the world hepatitis B free. Prevention Elsevier Treatment Elsevier Chronic hepatitis B Elsevier Hepatitis B vaccine Elsevier Hepatocellular carcinoma Elsevier Chronic liver disease Elsevier Public policy Elsevier Epidemiology Elsevier Acute hepatitis B Elsevier WHO Elsevier Hatzakis, Angelos oth Chen, Ding-Shinn oth Lok, Anna oth Enthalten in Elsevier Science Abdelbaky, Hanan H. ELSEVIER Identification of the antigenic region of 2018 official journal of the European Association for the Study of the Liver Amsterdam [u.a.] (DE-627)ELV000433829 volume:62 year:2015 number:1 pages:76-86 extent:11 https://doi.org/10.1016/j.jhep.2015.01.018 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.44 Parasitologie Medizin VZ AR 62 2015 1 76-86 11 62.2015, 1, S76-, (11 S.) 045F 610 |
| allfieldsGer |
10.1016/j.jhep.2015.01.018 doi GBVA2015006000007.pica (DE-627)ELV012879878 (ELSEVIER)S0168-8278(15)00049-5 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.44 bkl Locarnini, Stephen verfasserin aut Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs 2015transfer abstract 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The last 50years of hepatitis B research has resulted in the development of effective screening assays for surveillance, vaccines for prevention and antiviral drugs that significantly improve patient clinical outcomes. Not surprisingly then, the global epidemiology of hepatitis B virus (HBV) is set to change dramatically over the next decade. For example, the success and the high coverage of universal HBV vaccination and the ageing cohorts of patients with chronic hepatitis B (CHB) will result in reductions of incidence and prevalence of chronic hepatitis, cirrhosis and probably hepatocellular carcinoma. This will be further accelerated by the impressive progress in the treatment outcomes for patients with CHB. In spite of this success, challenges remain, such as planning for the impact of migration from countries with high prevalence rates to those countries with low rates of HBV infection. The recent establishment of the World Health Organisation Global Hepatitis Program with the provision of a framework for global action has become the cornerstone for all countries to now frame their own particular national responses to control hepatitis B. An effective policy framework can prevent new infections, ensure people can access clinical care, and in doing so reduce the burden of infection at an individual, country and regional level. These developments present a real opportunity to reduce the significant, social and economic burden of global hepatitis B, ultimately the critical next steps to render the world hepatitis B free. The last 50years of hepatitis B research has resulted in the development of effective screening assays for surveillance, vaccines for prevention and antiviral drugs that significantly improve patient clinical outcomes. Not surprisingly then, the global epidemiology of hepatitis B virus (HBV) is set to change dramatically over the next decade. For example, the success and the high coverage of universal HBV vaccination and the ageing cohorts of patients with chronic hepatitis B (CHB) will result in reductions of incidence and prevalence of chronic hepatitis, cirrhosis and probably hepatocellular carcinoma. This will be further accelerated by the impressive progress in the treatment outcomes for patients with CHB. In spite of this success, challenges remain, such as planning for the impact of migration from countries with high prevalence rates to those countries with low rates of HBV infection. The recent establishment of the World Health Organisation Global Hepatitis Program with the provision of a framework for global action has become the cornerstone for all countries to now frame their own particular national responses to control hepatitis B. An effective policy framework can prevent new infections, ensure people can access clinical care, and in doing so reduce the burden of infection at an individual, country and regional level. These developments present a real opportunity to reduce the significant, social and economic burden of global hepatitis B, ultimately the critical next steps to render the world hepatitis B free. Prevention Elsevier Treatment Elsevier Chronic hepatitis B Elsevier Hepatitis B vaccine Elsevier Hepatocellular carcinoma Elsevier Chronic liver disease Elsevier Public policy Elsevier Epidemiology Elsevier Acute hepatitis B Elsevier WHO Elsevier Hatzakis, Angelos oth Chen, Ding-Shinn oth Lok, Anna oth Enthalten in Elsevier Science Abdelbaky, Hanan H. ELSEVIER Identification of the antigenic region of 2018 official journal of the European Association for the Study of the Liver Amsterdam [u.a.] (DE-627)ELV000433829 volume:62 year:2015 number:1 pages:76-86 extent:11 https://doi.org/10.1016/j.jhep.2015.01.018 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.44 Parasitologie Medizin VZ AR 62 2015 1 76-86 11 62.2015, 1, S76-, (11 S.) 045F 610 |
| allfieldsSound |
10.1016/j.jhep.2015.01.018 doi GBVA2015006000007.pica (DE-627)ELV012879878 (ELSEVIER)S0168-8278(15)00049-5 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.44 bkl Locarnini, Stephen verfasserin aut Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs 2015transfer abstract 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The last 50years of hepatitis B research has resulted in the development of effective screening assays for surveillance, vaccines for prevention and antiviral drugs that significantly improve patient clinical outcomes. Not surprisingly then, the global epidemiology of hepatitis B virus (HBV) is set to change dramatically over the next decade. For example, the success and the high coverage of universal HBV vaccination and the ageing cohorts of patients with chronic hepatitis B (CHB) will result in reductions of incidence and prevalence of chronic hepatitis, cirrhosis and probably hepatocellular carcinoma. This will be further accelerated by the impressive progress in the treatment outcomes for patients with CHB. In spite of this success, challenges remain, such as planning for the impact of migration from countries with high prevalence rates to those countries with low rates of HBV infection. The recent establishment of the World Health Organisation Global Hepatitis Program with the provision of a framework for global action has become the cornerstone for all countries to now frame their own particular national responses to control hepatitis B. An effective policy framework can prevent new infections, ensure people can access clinical care, and in doing so reduce the burden of infection at an individual, country and regional level. These developments present a real opportunity to reduce the significant, social and economic burden of global hepatitis B, ultimately the critical next steps to render the world hepatitis B free. The last 50years of hepatitis B research has resulted in the development of effective screening assays for surveillance, vaccines for prevention and antiviral drugs that significantly improve patient clinical outcomes. Not surprisingly then, the global epidemiology of hepatitis B virus (HBV) is set to change dramatically over the next decade. For example, the success and the high coverage of universal HBV vaccination and the ageing cohorts of patients with chronic hepatitis B (CHB) will result in reductions of incidence and prevalence of chronic hepatitis, cirrhosis and probably hepatocellular carcinoma. This will be further accelerated by the impressive progress in the treatment outcomes for patients with CHB. In spite of this success, challenges remain, such as planning for the impact of migration from countries with high prevalence rates to those countries with low rates of HBV infection. The recent establishment of the World Health Organisation Global Hepatitis Program with the provision of a framework for global action has become the cornerstone for all countries to now frame their own particular national responses to control hepatitis B. An effective policy framework can prevent new infections, ensure people can access clinical care, and in doing so reduce the burden of infection at an individual, country and regional level. These developments present a real opportunity to reduce the significant, social and economic burden of global hepatitis B, ultimately the critical next steps to render the world hepatitis B free. Prevention Elsevier Treatment Elsevier Chronic hepatitis B Elsevier Hepatitis B vaccine Elsevier Hepatocellular carcinoma Elsevier Chronic liver disease Elsevier Public policy Elsevier Epidemiology Elsevier Acute hepatitis B Elsevier WHO Elsevier Hatzakis, Angelos oth Chen, Ding-Shinn oth Lok, Anna oth Enthalten in Elsevier Science Abdelbaky, Hanan H. ELSEVIER Identification of the antigenic region of 2018 official journal of the European Association for the Study of the Liver Amsterdam [u.a.] (DE-627)ELV000433829 volume:62 year:2015 number:1 pages:76-86 extent:11 https://doi.org/10.1016/j.jhep.2015.01.018 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.44 Parasitologie Medizin VZ AR 62 2015 1 76-86 11 62.2015, 1, S76-, (11 S.) 045F 610 |
| language |
English |
| source |
Enthalten in Identification of the antigenic region of Amsterdam [u.a.] volume:62 year:2015 number:1 pages:76-86 extent:11 |
| sourceStr |
Enthalten in Identification of the antigenic region of Amsterdam [u.a.] volume:62 year:2015 number:1 pages:76-86 extent:11 |
| format_phy_str_mv |
Article |
| bklname |
Parasitologie |
| institution |
findex.gbv.de |
| topic_facet |
Prevention Treatment Chronic hepatitis B Hepatitis B vaccine Hepatocellular carcinoma Chronic liver disease Public policy Epidemiology Acute hepatitis B WHO |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Identification of the antigenic region of |
| authorswithroles_txt_mv |
Locarnini, Stephen @@aut@@ Hatzakis, Angelos @@oth@@ Chen, Ding-Shinn @@oth@@ Lok, Anna @@oth@@ |
| publishDateDaySort_date |
2015-01-01T00:00:00Z |
| hierarchy_top_id |
ELV000433829 |
| dewey-sort |
3610 |
| id |
ELV012879878 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV012879878</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625111223.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180602s2015 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jhep.2015.01.018</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2015006000007.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV012879878</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0168-8278(15)00049-5</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.44</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Locarnini, Stephen</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">11</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The last 50years of hepatitis B research has resulted in the development of effective screening assays for surveillance, vaccines for prevention and antiviral drugs that significantly improve patient clinical outcomes. Not surprisingly then, the global epidemiology of hepatitis B virus (HBV) is set to change dramatically over the next decade. For example, the success and the high coverage of universal HBV vaccination and the ageing cohorts of patients with chronic hepatitis B (CHB) will result in reductions of incidence and prevalence of chronic hepatitis, cirrhosis and probably hepatocellular carcinoma. This will be further accelerated by the impressive progress in the treatment outcomes for patients with CHB. In spite of this success, challenges remain, such as planning for the impact of migration from countries with high prevalence rates to those countries with low rates of HBV infection. The recent establishment of the World Health Organisation Global Hepatitis Program with the provision of a framework for global action has become the cornerstone for all countries to now frame their own particular national responses to control hepatitis B. An effective policy framework can prevent new infections, ensure people can access clinical care, and in doing so reduce the burden of infection at an individual, country and regional level. These developments present a real opportunity to reduce the significant, social and economic burden of global hepatitis B, ultimately the critical next steps to render the world hepatitis B free.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The last 50years of hepatitis B research has resulted in the development of effective screening assays for surveillance, vaccines for prevention and antiviral drugs that significantly improve patient clinical outcomes. Not surprisingly then, the global epidemiology of hepatitis B virus (HBV) is set to change dramatically over the next decade. For example, the success and the high coverage of universal HBV vaccination and the ageing cohorts of patients with chronic hepatitis B (CHB) will result in reductions of incidence and prevalence of chronic hepatitis, cirrhosis and probably hepatocellular carcinoma. This will be further accelerated by the impressive progress in the treatment outcomes for patients with CHB. In spite of this success, challenges remain, such as planning for the impact of migration from countries with high prevalence rates to those countries with low rates of HBV infection. The recent establishment of the World Health Organisation Global Hepatitis Program with the provision of a framework for global action has become the cornerstone for all countries to now frame their own particular national responses to control hepatitis B. An effective policy framework can prevent new infections, ensure people can access clinical care, and in doing so reduce the burden of infection at an individual, country and regional level. These developments present a real opportunity to reduce the significant, social and economic burden of global hepatitis B, ultimately the critical next steps to render the world hepatitis B free.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Prevention</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Treatment</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Chronic hepatitis B</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Hepatitis B vaccine</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Hepatocellular carcinoma</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Chronic liver disease</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Public policy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Epidemiology</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Acute hepatitis B</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">WHO</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hatzakis, Angelos</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chen, Ding-Shinn</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lok, Anna</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Abdelbaky, Hanan H. ELSEVIER</subfield><subfield code="t">Identification of the antigenic region of</subfield><subfield code="d">2018</subfield><subfield code="d">official journal of the European Association for the Study of the Liver</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000433829</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:62</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:76-86</subfield><subfield code="g">extent:11</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jhep.2015.01.018</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.44</subfield><subfield code="j">Parasitologie</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">62</subfield><subfield code="j">2015</subfield><subfield code="e">1</subfield><subfield code="h">76-86</subfield><subfield code="g">11</subfield><subfield code="y">62.2015, 1, S76-, (11 S.)</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Locarnini, Stephen |
| spellingShingle |
Locarnini, Stephen ddc 610 bkl 44.44 Elsevier Prevention Elsevier Treatment Elsevier Chronic hepatitis B Elsevier Hepatitis B vaccine Elsevier Hepatocellular carcinoma Elsevier Chronic liver disease Elsevier Public policy Elsevier Epidemiology Elsevier Acute hepatitis B Elsevier WHO Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs |
| authorStr |
Locarnini, Stephen |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV000433829 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 610 VZ 44.44 bkl Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs Prevention Elsevier Treatment Elsevier Chronic hepatitis B Elsevier Hepatitis B vaccine Elsevier Hepatocellular carcinoma Elsevier Chronic liver disease Elsevier Public policy Elsevier Epidemiology Elsevier Acute hepatitis B Elsevier WHO Elsevier |
| topic |
ddc 610 bkl 44.44 Elsevier Prevention Elsevier Treatment Elsevier Chronic hepatitis B Elsevier Hepatitis B vaccine Elsevier Hepatocellular carcinoma Elsevier Chronic liver disease Elsevier Public policy Elsevier Epidemiology Elsevier Acute hepatitis B Elsevier WHO |
| topic_unstemmed |
ddc 610 bkl 44.44 Elsevier Prevention Elsevier Treatment Elsevier Chronic hepatitis B Elsevier Hepatitis B vaccine Elsevier Hepatocellular carcinoma Elsevier Chronic liver disease Elsevier Public policy Elsevier Epidemiology Elsevier Acute hepatitis B Elsevier WHO |
| topic_browse |
ddc 610 bkl 44.44 Elsevier Prevention Elsevier Treatment Elsevier Chronic hepatitis B Elsevier Hepatitis B vaccine Elsevier Hepatocellular carcinoma Elsevier Chronic liver disease Elsevier Public policy Elsevier Epidemiology Elsevier Acute hepatitis B Elsevier WHO |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
a h ah d s c dsc a l al |
| hierarchy_parent_title |
Identification of the antigenic region of |
| hierarchy_parent_id |
ELV000433829 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Identification of the antigenic region of |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV000433829 |
| title |
Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs |
| ctrlnum |
(DE-627)ELV012879878 (ELSEVIER)S0168-8278(15)00049-5 |
| title_full |
Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs |
| author_sort |
Locarnini, Stephen |
| journal |
Identification of the antigenic region of |
| journalStr |
Identification of the antigenic region of |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2015 |
| contenttype_str_mv |
zzz |
| container_start_page |
76 |
| author_browse |
Locarnini, Stephen |
| container_volume |
62 |
| physical |
11 |
| class |
610 610 DE-600 610 VZ 44.44 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Locarnini, Stephen |
| doi_str_mv |
10.1016/j.jhep.2015.01.018 |
| dewey-full |
610 |
| title_sort |
strategies to control hepatitis b: public policy, epidemiology, vaccine and drugs |
| title_auth |
Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs |
| abstract |
The last 50years of hepatitis B research has resulted in the development of effective screening assays for surveillance, vaccines for prevention and antiviral drugs that significantly improve patient clinical outcomes. Not surprisingly then, the global epidemiology of hepatitis B virus (HBV) is set to change dramatically over the next decade. For example, the success and the high coverage of universal HBV vaccination and the ageing cohorts of patients with chronic hepatitis B (CHB) will result in reductions of incidence and prevalence of chronic hepatitis, cirrhosis and probably hepatocellular carcinoma. This will be further accelerated by the impressive progress in the treatment outcomes for patients with CHB. In spite of this success, challenges remain, such as planning for the impact of migration from countries with high prevalence rates to those countries with low rates of HBV infection. The recent establishment of the World Health Organisation Global Hepatitis Program with the provision of a framework for global action has become the cornerstone for all countries to now frame their own particular national responses to control hepatitis B. An effective policy framework can prevent new infections, ensure people can access clinical care, and in doing so reduce the burden of infection at an individual, country and regional level. These developments present a real opportunity to reduce the significant, social and economic burden of global hepatitis B, ultimately the critical next steps to render the world hepatitis B free. |
| abstractGer |
The last 50years of hepatitis B research has resulted in the development of effective screening assays for surveillance, vaccines for prevention and antiviral drugs that significantly improve patient clinical outcomes. Not surprisingly then, the global epidemiology of hepatitis B virus (HBV) is set to change dramatically over the next decade. For example, the success and the high coverage of universal HBV vaccination and the ageing cohorts of patients with chronic hepatitis B (CHB) will result in reductions of incidence and prevalence of chronic hepatitis, cirrhosis and probably hepatocellular carcinoma. This will be further accelerated by the impressive progress in the treatment outcomes for patients with CHB. In spite of this success, challenges remain, such as planning for the impact of migration from countries with high prevalence rates to those countries with low rates of HBV infection. The recent establishment of the World Health Organisation Global Hepatitis Program with the provision of a framework for global action has become the cornerstone for all countries to now frame their own particular national responses to control hepatitis B. An effective policy framework can prevent new infections, ensure people can access clinical care, and in doing so reduce the burden of infection at an individual, country and regional level. These developments present a real opportunity to reduce the significant, social and economic burden of global hepatitis B, ultimately the critical next steps to render the world hepatitis B free. |
| abstract_unstemmed |
The last 50years of hepatitis B research has resulted in the development of effective screening assays for surveillance, vaccines for prevention and antiviral drugs that significantly improve patient clinical outcomes. Not surprisingly then, the global epidemiology of hepatitis B virus (HBV) is set to change dramatically over the next decade. For example, the success and the high coverage of universal HBV vaccination and the ageing cohorts of patients with chronic hepatitis B (CHB) will result in reductions of incidence and prevalence of chronic hepatitis, cirrhosis and probably hepatocellular carcinoma. This will be further accelerated by the impressive progress in the treatment outcomes for patients with CHB. In spite of this success, challenges remain, such as planning for the impact of migration from countries with high prevalence rates to those countries with low rates of HBV infection. The recent establishment of the World Health Organisation Global Hepatitis Program with the provision of a framework for global action has become the cornerstone for all countries to now frame their own particular national responses to control hepatitis B. An effective policy framework can prevent new infections, ensure people can access clinical care, and in doing so reduce the burden of infection at an individual, country and regional level. These developments present a real opportunity to reduce the significant, social and economic burden of global hepatitis B, ultimately the critical next steps to render the world hepatitis B free. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| container_issue |
1 |
| title_short |
Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs |
| url |
https://doi.org/10.1016/j.jhep.2015.01.018 |
| remote_bool |
true |
| author2 |
Hatzakis, Angelos Chen, Ding-Shinn Lok, Anna |
| author2Str |
Hatzakis, Angelos Chen, Ding-Shinn Lok, Anna |
| ppnlink |
ELV000433829 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth |
| doi_str |
10.1016/j.jhep.2015.01.018 |
| up_date |
2024-07-06T17:24:22.338Z |
| _version_ |
1803851307248779264 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV012879878</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625111223.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180602s2015 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jhep.2015.01.018</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2015006000007.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV012879878</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0168-8278(15)00049-5</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.44</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Locarnini, Stephen</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">11</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The last 50years of hepatitis B research has resulted in the development of effective screening assays for surveillance, vaccines for prevention and antiviral drugs that significantly improve patient clinical outcomes. Not surprisingly then, the global epidemiology of hepatitis B virus (HBV) is set to change dramatically over the next decade. For example, the success and the high coverage of universal HBV vaccination and the ageing cohorts of patients with chronic hepatitis B (CHB) will result in reductions of incidence and prevalence of chronic hepatitis, cirrhosis and probably hepatocellular carcinoma. This will be further accelerated by the impressive progress in the treatment outcomes for patients with CHB. In spite of this success, challenges remain, such as planning for the impact of migration from countries with high prevalence rates to those countries with low rates of HBV infection. The recent establishment of the World Health Organisation Global Hepatitis Program with the provision of a framework for global action has become the cornerstone for all countries to now frame their own particular national responses to control hepatitis B. An effective policy framework can prevent new infections, ensure people can access clinical care, and in doing so reduce the burden of infection at an individual, country and regional level. These developments present a real opportunity to reduce the significant, social and economic burden of global hepatitis B, ultimately the critical next steps to render the world hepatitis B free.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The last 50years of hepatitis B research has resulted in the development of effective screening assays for surveillance, vaccines for prevention and antiviral drugs that significantly improve patient clinical outcomes. Not surprisingly then, the global epidemiology of hepatitis B virus (HBV) is set to change dramatically over the next decade. For example, the success and the high coverage of universal HBV vaccination and the ageing cohorts of patients with chronic hepatitis B (CHB) will result in reductions of incidence and prevalence of chronic hepatitis, cirrhosis and probably hepatocellular carcinoma. This will be further accelerated by the impressive progress in the treatment outcomes for patients with CHB. In spite of this success, challenges remain, such as planning for the impact of migration from countries with high prevalence rates to those countries with low rates of HBV infection. The recent establishment of the World Health Organisation Global Hepatitis Program with the provision of a framework for global action has become the cornerstone for all countries to now frame their own particular national responses to control hepatitis B. An effective policy framework can prevent new infections, ensure people can access clinical care, and in doing so reduce the burden of infection at an individual, country and regional level. These developments present a real opportunity to reduce the significant, social and economic burden of global hepatitis B, ultimately the critical next steps to render the world hepatitis B free.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Prevention</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Treatment</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Chronic hepatitis B</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Hepatitis B vaccine</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Hepatocellular carcinoma</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Chronic liver disease</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Public policy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Epidemiology</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Acute hepatitis B</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">WHO</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hatzakis, Angelos</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chen, Ding-Shinn</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lok, Anna</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Abdelbaky, Hanan H. ELSEVIER</subfield><subfield code="t">Identification of the antigenic region of</subfield><subfield code="d">2018</subfield><subfield code="d">official journal of the European Association for the Study of the Liver</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000433829</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:62</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:76-86</subfield><subfield code="g">extent:11</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jhep.2015.01.018</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.44</subfield><subfield code="j">Parasitologie</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">62</subfield><subfield code="j">2015</subfield><subfield code="e">1</subfield><subfield code="h">76-86</subfield><subfield code="g">11</subfield><subfield code="y">62.2015, 1, S76-, (11 S.)</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.4012156 |